EP1620070A2 - Tr9 (toll-like receptor 9) effektor-mittel und ihre verwendungen - Google Patents

Tr9 (toll-like receptor 9) effektor-mittel und ihre verwendungen

Info

Publication number
EP1620070A2
EP1620070A2 EP04751272A EP04751272A EP1620070A2 EP 1620070 A2 EP1620070 A2 EP 1620070A2 EP 04751272 A EP04751272 A EP 04751272A EP 04751272 A EP04751272 A EP 04751272A EP 1620070 A2 EP1620070 A2 EP 1620070A2
Authority
EP
European Patent Office
Prior art keywords
tlr9
binding agent
human
ligand binding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04751272A
Other languages
English (en)
French (fr)
Inventor
Ashlyn Bassiri
Anuk Das
Susan Dillon
Karen Duffy
Jonathan Seideman
Lars Karlsson
Sun Siquan
Jian Zhu
M. Lamine Mbow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP1620070A2 publication Critical patent/EP1620070A2/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
EP04751272A 2003-04-29 2004-04-29 Tr9 (toll-like receptor 9) effektor-mittel und ihre verwendungen Ceased EP1620070A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46634103P 2003-04-29 2003-04-29
PCT/US2004/013816 WO2004096156A2 (en) 2003-04-29 2004-04-29 Toll-like receptor 9 effector agents and uses thereof

Publications (1)

Publication Number Publication Date
EP1620070A2 true EP1620070A2 (de) 2006-02-01

Family

ID=33418366

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04751272A Ceased EP1620070A2 (de) 2003-04-29 2004-04-29 Tr9 (toll-like receptor 9) effektor-mittel und ihre verwendungen

Country Status (3)

Country Link
EP (1) EP1620070A2 (de)
CA (1) CA2524071A1 (de)
WO (1) WO2004096156A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
US8188058B2 (en) 2007-04-19 2012-05-29 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
JP5563455B2 (ja) * 2007-08-01 2014-07-30 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の新規な合成アゴニスト
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
US9562066B2 (en) 2012-09-25 2017-02-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192217A1 (en) * 2001-03-07 2002-12-19 Thierry Calandra Methods for regulation of immune responses to conditions involving mediator-induced pathology

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004096156A3 *

Also Published As

Publication number Publication date
CA2524071A1 (en) 2004-11-11
WO2004096156A3 (en) 2009-04-02
WO2004096156A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
US11359020B2 (en) Agents that modulate immune cell activation and methods of use thereof
JP4754219B2 (ja) 腫瘍壊死因子を対象とする抗体、およびそれらの使用
TWI820031B (zh) 結合人類cd137之促效劑抗體及其用途
JP5677744B2 (ja) ヒトＤｅｌｔａ様リガンド４に対するヒト抗体
JP3675819B2 (ja) Ｃｄ４０に対する抗体
CA2563313C (en) Modulation of nkg2d
US20170044262A1 (en) Humanized monoclonal antibodies and methods of use
KR20180127971A (ko) 신규 항-pd-l1 항체
RU2769352C2 (ru) Антитела и полипептиды, направленные против cd127
US8367356B2 (en) Gelsolin binding agent compositions and uses of same
KR20090029184A (ko) 항체 조성물 및 신생물성 질병의 치료 방법
PT1963369E (pt) Antagonistas de il-21
JP7053479B2 (ja) ＩＬ７受容体細胞外ドメインα鎖に対する非拮抗性抗体及び癌治療におけるそれらの使用
JP2010229156A (ja) 早期活性化分子のターゲティングに基づく免疫調節
US9688769B2 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
WO2019084307A1 (en) ANTI-MERTK ANTIBODIES AND METHODS OF USE
JP2022527506A (ja) Ｃｄ４０活性化特性を有する組換えタンパク質
KR20220092584A (ko) 항tigit 항체 및 이의 용도
JP2007525416A5 (de)
EP1620070A2 (de) Tr9 (toll-like receptor 9) effektor-mittel und ihre verwendungen
JP2008502368A (ja) Ｓｉｇｌｅｃ−６関連疾患の診断および処置
JP6159011B2 (ja) Ｃｄ９に対するハイブリドーマクローンおよびモノクローナル抗体
US20050244410A1 (en) Toll-like receptor 9 effector agents and uses thereof
WO2020205576A1 (en) Anti-axl antibodies and methods of use thereof
US20230055411A1 (en) Monoclonal antibody against stim1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20090518BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100501